Cardiovascular diagnosis and therapy最新文献

{"title":"Challenges in clinical translation of cardiac magnetic resonance imaging radiomics in non-ischemic cardiomyopathy: a narrative review.","authors":"Jia Deng, Langtao Zhou, Bihong Liao, Qinxi Cai, Guanghua Luo, Hong Zhou, Huifang Tang","doi":"10.21037/cdt-24-138","DOIUrl":"10.21037/cdt-24-138","url":null,"abstract":"<p><strong>Background and objective: </strong>Radiomics is an emerging technology that facilitates the quantitative analysis of multi-modal cardiac magnetic resonance imaging (MRI). This study aims to introduce a standardized workflow for applying radiomics to non-ischemic cardiomyopathies, enabling clinicians to comprehensively understand and implement this technology in clinical practice.</p><p><strong>Methods: </strong>A computerized literature search (up to August 1, 2024) was conducted using PubMed to identify relevant studies on the roles and workflows of radiomics in non-ischemic cardiomyopathy. Expert discussions were also held to ensure the accuracy and relevance of the findings. Only English-language publications were reviewed.</p><p><strong>Key content and findings: </strong>The paper details the essential processes of radiomics, including feature extraction, feature engineering, model construction, and data analysis. It emphasizes the role of MRI in assessing cardiac structure and function and demonstrates how MRI-based radiomics can aid in diagnosing and differentiating non-ischemic cardiomyopathies such as hypertrophic cardiomyopathy, dilated cardiomyopathy, and myocarditis. The study also investigates various cardiac MRI sequences to enhance the clinical application of radiomics.</p><p><strong>Conclusions: </strong>The standardized radiomics workflow presented in this study aims to assist clinicians in effectively utilizing MRI-based radiomics for the diagnosis and management of non-ischemic cardiomyopathies, thereby improving clinical decision-making.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 6","pages":"1210-1227"},"PeriodicalIF":2.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy & cardiovascular disease: the PREG-CVD-HH registry.","authors":"Dora Csengeri, Elisabeth Unger, Jessica Weimann, Michael Huntgeburth, Yskert von Kodolitsch, Tanja Zeller, Stefan Blankenberg, Paulus Kirchhof, Anke Diemert, Renate B Schnabel, Christoph R Sinning, Elvin Zengin-Sahm","doi":"10.21037/cdt-24-248","DOIUrl":"10.21037/cdt-24-248","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cardiovascular disease (CVD) remains the leading cause of death in pregnant and peripartal women in western countries. Physiological changes during pregnancy can lead to cardiovascular complications in the mother; women with pre-existing heart disease may not tolerate these changes well, increasing their susceptibility to adverse cardiovascular outcomes during pregnancy. The aim of this study is to characterize pregnancy-induced changes in cardiac function, biomarker concentrations and cardiovascular outcomes in women with CVD during pregnancy at a tertiary care hospital in Germany.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The PREG-CVD-HH study is a prospective single-center observational study of pregnant women with prevalent CVD treated at the University Medical Center Hamburg, Germany and currently includes 63 women with congenital or acquired heart disease and ten women from the general population included as controls. Participants underwent baseline assessment and dedicated comprehensive echocardiography. Biomarkers N-terminal pro B-type natriuretic peptide (NT-proBNP), MR-proadrenomedullin (MRproADM) and high-sensitivity cardiac troponin I (hs-cTnI) were measured serially throughout pregnancy and until 6 and 12 months postpartum. A maternal cardiac event was defined as death due to cardiovascular cause, arrhythmia, heart failure or hospitalization for other cardiac intervention.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Mean maternal age was 34 years. A majority had a congenital heart disease (N=41), 10 patients developed pregnancy-associated CVD (e.g., preeclampsia, peripartum cardiomyopathy) and 12 women had known acquired heart disease (e.g., valvular disease, arrhythmia, cardiomyopathy). New-onset heart failure was observed in 14.1% of patients (N=9). Five patients developed arrhythmia and three patients developed preeclampsia. About 21.2% of patients were hospitalized due to cardiovascular events. Death from any or cardiovascular cause did not occur over the study period. Left and right ventricular global longitudinal strain (LV GLS, RV GLS) showed a transient worsening in the third trimester and peripartum period. NT-proBNP ranges broadened during the pregnancy and tended to progressively decrease postpartum in women with CVD. Hs-cTnI levels tended to trend upwards during pregnancy in patients with CVD, however, the hs-cTnI levels remained consistently low throughout pregnancy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In our cohort, pregnancy was associated with a transient increase in cardiac biomarkers and worsening of cardiac function during the third trimester and peripartum. These temporal changes reversed at 6-12 months postpartum, potentially due to decreased cardiac load, fluid shifts and hormonal changes. Overall, data on reference ranges in echocardiographic and biomarker measurements in the pregnant cardiac population are limited and require further investigation. Albeit one third of our cohort was deemed at high an","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 6","pages":"1058-1069"},"PeriodicalIF":2.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Procedural success prediction in chronic total occlusion percutaneous coronary intervention (CTO-PCI)-the rise of the machines?","authors":"Claudiu Ungureanu, Gregor Leibundgut","doi":"10.21037/cdt-24-392","DOIUrl":"10.21037/cdt-24-392","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 6","pages":"994-997"},"PeriodicalIF":2.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized trial comparing a stent-avoiding with a stent-preferred strategy in complex femoropopliteal lesions.","authors":"Gemmi Sufali, Martin Teraa","doi":"10.21037/cdt-24-384","DOIUrl":"10.21037/cdt-24-384","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 6","pages":"1011-1014"},"PeriodicalIF":2.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sirolimus coated balloon for the treatment of femoropopliteal lesions: the new kid on the block is getting older 'step by step'.","authors":"Konstantinos P Donas, Christos Rammos, Grigorios Korosoglou","doi":"10.21037/cdt-24-406","DOIUrl":"10.21037/cdt-24-406","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 6","pages":"1015-1019"},"PeriodicalIF":2.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reporting quality of animal research in journals that published the ARRIVE 1.0 or ARRIVE 2.0 guidelines: a cross-sectional analysis of 943 studies.","authors":"Yao Lin, Fanghui Yang, Binghan Shang, John E Speich, Yu-Jui Yvonne Wan, Hiroki Hashida, Tobias Braun, Ali Sadoughi, Thomas Puehler, Tom F Lue, Kaiping Zhang","doi":"10.21037/cdt-24-413","DOIUrl":"10.21037/cdt-24-413","url":null,"abstract":"<p><strong>Background: </strong>The adherence to the Animals in Research: Reporting In Vivo Experiments (ARRIVE) guidelines across the journals that initially published the guidelines and if adherence has improved since the guidelines update, remains unknown. We aimed to quantify the level of adherence and analyze factors that might influence reporting quality among these journals.</p><p><strong>Methods: </strong>This cross-sectional study retrospectively analyzed interventional animal experiments published in journals that released ARRIVE 1.0 and 2.0 guidelines in three periods: 5 years before (Pre-ARRIVE 1.0) and after (Post-ARRIVE 1.0) the publication of ARRIVE 1.0, and 1 year after the publication of ARRIVE 2.0 (Post-ARRIVE 2.0). Reviewers independently assessed adherence to the ARRIVE guidelines. Basic information and potential influencing factors were extracted. Adherence data were presented as frequency (percentages). Statistical factors influencing reporting quality were evaluated using the Chi-square test or Fisher's exact test.</p><p><strong>Results: </strong>215, 330, and 398 experiments were included during Pre-ARRIVE 1.0, Post-ARRIVE 1.0 and Post-ARRIVE 2.0 periods, respectively. None of the included 943 studies reported all 38 subitems, showing only 0%, 0%, and 0.25% studies had an \"excellent\" reporting quality across the three periods. The overall reporting quality was significantly improved among Pre-ARRIVE 1.0, Post-ARRIVE 1.0 and Post-ARRIVE 2.0 (P<0.001). The rate of studies with \"average\" reporting quality increased sequentially from 53.95% to 73.94% and then to 90.20%, and those with \"poor\" reporting quality decreased sequentially from 46.05% to 26.06% and then to 9.55% across the three periods. Specifically, 15 out of 38 (39.5%) subitems and 11 out of 27 (40.7%) similar and comparable subitems demonstrated a significant higher percentage of \"fully reported\" in Post-ARRIVE 1.0 compared to Pre-ARRIVE 1.0 and in Post-ARRIVE 2.0 compared to Post-ARRIVE 1.0, respectively (P<0.05). Country and journal indexing did not significantly affect reporting quality (both P>0.05). However, significant differences in reporting quality were found among the mandatory adherence to the ARRIVE guidelines in the author's instructions and reference to ARRIVE in the manuscript (both P<0.001).</p><p><strong>Conclusions: </strong>In the journals that initially published the ARRIVE guidelines, compliance with the guidelines still has room for improvement, though it has increased sequentially since introducing the guidelines. Implementing mandatory adherence requirements in the author's instructions and explicitly recognizing adherence to ARRIVE in articles could enhance the reporting quality of interventional animal experiments.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 6","pages":"1070-1082"},"PeriodicalIF":2.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sirolimus-coated balloons for peripheral arterial disease: walking free into the future of endovascular treatment.","authors":"Riccardo M Fumagalli, Stefano Barco","doi":"10.21037/cdt-24-484","DOIUrl":"10.21037/cdt-24-484","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 6","pages":"987-990"},"PeriodicalIF":2.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interlinking pathways: a narrative review on the role of IL-6 in cancer and atherosclerosis.","authors":"Riccardo Cau, Luca Saba","doi":"10.21037/cdt-24-344","DOIUrl":"10.21037/cdt-24-344","url":null,"abstract":"<p><strong>Background and objective: </strong>Interleukin-6 (IL-6) plays multifaceted roles in cancer and atherosclerosis. Initially recognized for its role in immune response and inflammation, IL-6 promotes tumor progression via the JAK-STAT and MAP kinase pathways and is associated with poor cancer prognoses. In atherosclerosis, IL-6 contributes to endothelial dysfunction and plaque formation. This review highlights the shared inflammatory mechanisms of IL-6 in both diseases and explores the regulatory dynamics of IL-6 signaling, including gene polymorphisms and epigenetic modifications.</p><p><strong>Methods: </strong>Google Scholar, Scopus, and PubMed were searched for English-language articles on IL-6 and those reporting shared pathogenic mechanisms of IL-6 in cancer and atherosclerosis from their inception through June 2024.</p><p><strong>Key content and findings: </strong>The investigation into IL-6's mechanisms in cancer and atherosclerosis reveals the intricate and interconnected nature of inflammatory processes in chronic diseases. The role of IL-6 in both conditions underscores its centrality in disease pathology, particularly through its involvement in inflammation, immune modulation, and cellular proliferation. This commonality highlights IL-6 as a key player linking these seemingly distinct diseases.</p><p><strong>Conclusions: </strong>Given the shared pathogenic mechanism of IL-6 in cancer and atherosclerosis, this narrative review concludes by emphasizing the therapeutic potential of modulating IL-6 in treating both cancer and atherosclerosis. It advocates for personalized treatment strategies that combine targeted therapies with lifestyle modifications. This holistic approach is considered crucial for effective disease management, given the diverse and complex roles IL-6 plays in these widespread conditions.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 6","pages":"1186-1201"},"PeriodicalIF":2.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L-shaped association between gamma-glutamyl transferase-to-albumin ratio and dabigatran-related bleeding in non-valvular atrial fibrillation patients: a multicenter cohort study.","authors":"Chao Yu, Tao Wang, Lingjuan Zhu, Wei Zhou, Huihui Bao, Xiaoshu Cheng","doi":"10.21037/cdt-24-258","DOIUrl":"https://doi.org/10.21037/cdt-24-258","url":null,"abstract":"<p><strong>Background: </strong>The correlation between the gamma-glutamyl transferase-to-albumin ratio (GAR) and the risk of bleeding in patients with non-valvular atrial fibrillation (NVAF) undergoing treatment with the dabigatran anticoagulant is poorly understood. This study aims to explore whether GAR is associated with bleeding events among patients with NVAF receiving dabigatran anticoagulant therapy.</p><p><strong>Methods: </strong>We conducted a multicenter, observational cohort study in 12 Chinese hospitals from six provinces, including Beijing, Shanghai and Guangzhou, to evaluate the effectiveness and safety of dabigatran (110 mg) treatment in NVAF patients who were consecutively enrolled during February 2015 and December 2017. All patients had completed a 3-month follow-up period. The baseline variable of interest was the GAR, and the outcome variable was the occurrence of bleeding events. Both univariate and multivariate Cox proportional hazard models were used to evaluate the relationship between GAR and bleeding outcome.</p><p><strong>Results: </strong>This prospective cohort study included a total of 834 patients (mean age 65.6±11.1 years; 56.8% male). Overall, 82 subjects experienced bleeding. The patients were categorized based on the tertiles of the GAR. Participants in tertile 2 (0.59-1.03) [hazard ratio (HR): 0.28; 95% confidence interval (CI): 0.14-0.55; P<0.001] and tertile 3 (≥1.04) (HR: 0.47; 95% CI: 0.25-0.89; P=0.02) exhibited a lower rate of bleeding compared to the reference group (T1: ≤0.58). Multivariable models with restricted cubic splines demonstrated a nonlinear relationship between GAR and bleeding outcome, with a GAR inflection point of 0.68. The HR (95% CI) was 0.05 (0.01-0.31) (P=0.002) for GAR values <0.68 and 0.96 (0.70-1.31) (P=0.78) for GAR values ≥0.68. Moreover, the correlation between decreased GAR and an increase in bleeding events remained consistent across various subgroups.</p><p><strong>Conclusions: </strong>GAR is a prevalent, independent predictor of dabigatran-related bleeding in NVAF patients. Moreover, a significant L-shaped association between GAR and bleeding events has been observed.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"848-858"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary mitral regurgitation surgical management: a narrative review.","authors":"Sarah R Eapen, Mina H Zaky, Megan P Kostibas, Michael P Robich","doi":"10.21037/cdt-24-6","DOIUrl":"https://doi.org/10.21037/cdt-24-6","url":null,"abstract":"<p><strong>Background and objective: </strong>The most common valvular heart disease in the US is moderate to severe mitral regurgitation (MR). Function MR or secondary MR comprises many of these cases. Moderate and severe secondary MR are independently associated with increased all-cause mortality and rehospitalization for heart failure. Both ischemic and nonischemic cardiomyopathy can cause secondary MR via similar pathophysiology that leads to inadequate valve leaflets coaptation. The management of secondary MR is complex. The optimal treatment strategy for secondary MR remains controversial, reflected in the vast array of treatment options and the complexity of therapeutic decision-making. Several surgical mitral valve repair techniques have been described in the literature. Many of these aims to facilitate adequate valve leaflet coaptation. In this review, the pathophysiology of MR is described with a focus on evaluating and managing secondary MR.</p><p><strong>Methods: </strong>A literature review was performed using PubMed and Google Scholar. Clinical trials, meta-analyses, randomized controlled trials, reviews, and systematic reviews were considered from January 1, 1995 through December 31, 2022. Articles published in languages other than English with limited text availability were excluded.</p><p><strong>Key content and findings: </strong>Optimal therapeutic approach in severe secondary MR is complex and several patient factor should be considered. We provide a framework for the surgical management of secondary MR based on echocardiographic parameters, the presence of ischemia, and myocardial viability.</p><p><strong>Conclusions: </strong>Further study is needed to guide the selection of patients most likely to benefit from mitral valve repair or replacement in the setting of secondary MR.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"14 5","pages":"958-973"},"PeriodicalIF":2.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}